Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Study: Happy people tend to live longer and experience better health

A review of more than 160 studies of human and animal subjects has found "clear and compelling evidence" that - all else being equal - happy people tend to live longer and experience better health than their unhappy peers.

1 Mar 2011

New study: No decline in breast cancer incidence rates among U.S. white women

A sharp decline in breast cancer incidence rates among non-Hispanic white women in the U.S. after a dramatic drop in the use of postmenopausal hormone therapy did not continue through 2007, according to a new study from the American Cancer Society and the National Cancer Institute.

1 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P..

28 Feb 2011

Researchers discover new mechanism of beta cell destruction not previously known

The death of insulin-producing beta cells in the pancreas is a core defect in diabetes. Scientists in Italy and Texas now have discovered a new way that these cells die - by toxic imbalance of a molecule secreted by other pancreatic cells.

28 Feb 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Hashimoto's thyroiditis, an inflammatory disorder of the thyroid, is the most common cause of hypothyroidism, but a study has suggested that even when thyroid function is normal, HT may increase symptoms and decrease quality of life, as described in an article in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.

27 Feb 2011

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Warner Chilcott plc today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010.

25 Feb 2011

Evolutionary changes may have influenced metabolism and increased risk of diabetes

Researchers at the University of California, San Diego School of Medicine and Rady Children's Hospital-San Diego say an evolutionary gene mutation that occurred in human millions of years ago and our subsequent inability to produce a specific kind of sugar molecule appears to make people more vulnerable to developing type 2 diabetes, especially if they're overweight.

25 Feb 2011

PACAP hormone levels linked to post-traumatic stress disorder

High blood levels of a hormone produced in response to stress are linked to post-traumatic stress disorder in women but not men, a study from researchers at Emory University and the University of Vermont has found.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists from Karolinska Institutet in Sweden shows in an international collaboration involving colleagues from Germany and Switzerland. The study is published in the recent issue of Immunity, and sheds some new light on the biological function of heparin.

25 Feb 2011

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.

25 Feb 2011

New study: Multiple full-term pregnancies may have higher risk of 'triple-negative' breast cancer

Full-term pregnancy has long been associated with a reduced risk of breast cancer, but a new study finds that the more times a woman gives birth, the higher her risk of "triple-negative" breast cancer, a relatively uncommon but particularly aggressive subtype of the disease.

24 Feb 2011

Study: Individuals with fatty liver more likely to develop type 2 diabetes

A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism found that individuals with fatty liver were five times more likely to develop type 2 diabetes than those without fatty liver. This higher risk seemed to occur regardless of the patient's fasting insulin levels, which were used as a marker of insulin resistance.

24 Feb 2011

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

24 Feb 2011

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk announced today that a Biologic License Application has been submitted to the U.S. Food and Drug Administration requesting the approval of a recombinant factor XIII compound for the vast majority of patients with congenital factor XIII deficiency, an inherited bleeding disorder.

From Novo Nordisk 23 Feb 2011

Biological pathways in PTSD revealed: Study

Up to 20% of the population exposed to a horror of a war, trauma or abuse may go on to develop post-traumatic stress disorder. PTSD, as it is better known, is a debilitating psychiatric disorder marked by flashbacks and nightmares. Till date the biological basis for PTSD was unclear. But a new study offers clues about why some people rebound from horrific events while others relive them, and may lead to predictive tests and even treatments.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

Hormone News and Research

Further Reading

Study: Happy people tend to live longer and experience better health

New study: No decline in breast cancer incidence rates among U.S. white women

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Researchers discover new mechanism of beta cell destruction not previously known

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Evolutionary changes may have influenced metabolism and increased risk of diabetes

PACAP hormone levels linked to post-traumatic stress disorder

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Study: Heparin plays a key role in mast cell-driven allergic and inflammatory reactions

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

New study: Multiple full-term pregnancies may have higher risk of 'triple-negative' breast cancer

Study: Individuals with fatty liver more likely to develop type 2 diabetes

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Biological pathways in PTSD revealed: Study

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News